Artificial Intelligence
Anthropic sets up biology lab for robot-guided experiments
Anthropic was building a biology lab in the San Francisco area to carry out physical experiments with Claude guiding robots, while saying human oversight would still be needed for safety.
- Anthropic was building a biology lab in the San Francisco area, Reuters reported.
- The lab was intended to let the company run physical experiments rather than rely only on simulations.
- Anthropic said Claude would guide robots through experiments with limited human involvement, and that people would still oversee the work for safety.
- Eric Kauderer-Abrams said the main opportunity was in diseases considered undruggable, and that AI could help design complex antibodies.
- In April, Anthropic acquired Coefficient Bio for about $400 million and added Novartis chief executive Vas Narasimhan to its board; the report said it would not run its own clinical trials for now.
Anthropic was building a biology lab in the San Francisco area so it could carry out physical experiments, Reuters reported. The plan was for Claude to direct robots through the work with little human intervention.
The company said it had already released two tools for that setup: Claude Science, which it described as a workspace for researchers, and the Model Hardware Standard for lab equipment. Anthropic said human oversight would still be needed for safety.
Eric Kauderer-Abrams, who led Anthropic’s life sciences division, said the biggest opportunity lay in diseases that had no treatment options. He said AI could help design complex antibodies that acted on multiple targets.
The move followed Anthropic’s April purchase of Coefficient Bio for about $400 million and the addition of Novartis chief executive Vas Narasimhan to its board. The report said the company was not planning to run clinical trials itself at this stage.
Named in this story
People
- Eric Kauderer-Abrams
- runs Anthropic’s life sciences division and described its aims
- Vas Narasimhan
- was added to Anthropic’s board
Companies
- Anthropic
- was building the biology lab and providing the AI tools
- Coefficient Bio
- was acquired by Anthropic in April
- Novartis
- was the company led by Vas Narasimhan
Organisations
- Reuters
- reported the lab plans
Products and systems
- Claude
- was to guide robots through experiments
- Claude Science
- was described as a workspace for researchers
- Model Hardware Standard
- was made for controlling lab equipment
Places
- San Francisco area
- was where the lab was located
How the source tells it
The source was mostly factual, with a light promotional cast from Anthropic’s own ambitions for AI-assisted drug discovery.
- forward-looking optimism the headline and lead built a future-facing setup around a new lab and robot-guided experiments
- vendor boosterism the company’s claims about speeding drug discovery were repeated as a central part of the story